Logan Lutton

Aetna has released the details of its Medicare Advantage plans for 2026, which focus on preventative care and drug cost savings.

Rhapsido is the first and only Bruton’s tyrosine kinase (BTK) inhibitor approved for chronic spontaneous urticaria (CSU).

SCAN Health Plan will expand its 2026 Medicare Advantage benefits with $0 copays and higher dental, vision and allowance coverage amid funding and coverage cuts from larger insurers such as UnitedHealthcare and Aetna.

Enrollment in Medicare Advantage Special Needs Plans (SNPs) has grown steadily since becoming permanent in 2018, now accounting for 21% of Medicare Advantage enrollees, with recent growth driven by chronic condition SNPs surpassing dual-eligible SNPs due to changing CMS requirements, according to a new KFF report.

Insulin will be available through Sanofi’s Insulins Valyou Savings Program starting January 1, 2026.

Here’s what you missed this week on Managed Healthcare Executive.

Evkeeza is now approved for the treatment of homozygous familial hypercholesterolemia (HoFH) in patients as young as 1 year old.

Tavapadon is an investigational, novel, once-daily treatment option for Parkinson’s disease, which currently affects more than 1 million Americans.

Today’s announcement builds on a previous announcement of more than 40% off the Eliquis list price, a direct-to-consumer program that began earlier this month.

Robert Gamble, CEO of RxBenefits, shares how Illuminate Rx does specialty, plus the areas they will continue to innovate on.

The FDA letter requested that a technical information update be included in the Chemistry Manufacturing and Controls (CMC) module of the sNDA.

Yael Bensoussan, M.D., director of the University of South Florida Health Voice Center, discusses menopause-related voice changes and how artificial intelligence is being used to address them.

The complete response letter was issued by the FDA during a routine inspection of a third-party fill-finish facility, not because of an issue with apitegromab.

Data quality issues and increased rates of claim denials provide opportunities for artificial intelligence to make improvements, according to a recent survey by Experian Health.

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s disease.

Here’s what you missed this week on Managed Healthcare Executive.

On the second day of its meeting, the Advisory Committee on Immunization Practices (ACIP) postponed a decision on giving hepatitis B vaccines at birth and revoted against coverage of the combined MMRV vaccine under the Vaccines for Children program.

RxBenefits is aiming to fill gaps in the PBM market with a new option for self-funded employers and brokers, called Illuminate Rx.

This spray formulation of bumetanide demonstrated a 33% faster absorption rate than oral bumetanide, according to clinical trial data.

Nearly half of women experience hormone-driven vocal changes during menopause, which may alter voice quality and affect those in voice-reliant careers, a new review finds.

RxBenefits has released Illuminate Rx, a new PBM aiming to fill gaps in the current PBM market, according to Robert Gamble, CEO of RxBenefits.

Advances in HIV medication, its window of detection and its transmission risk within the last decade have led to an updated version of the HIV exposure protocol for healthcare personnel.

Elevated levels of the gut hormone GLP-1 and its receptor may worsen brain inflammation and trigger severe symptoms in patients with neuromyelitis optica spectrum disorder (NMOSD), suggesting GLP-1 drugs could pose risks for this rare autoimmune disease.

Results show that GLP-1s may address rheumatoid arthritis (RA) symptoms, independent of established weight loss and cardiac benefits, by reducing the systemic, chronic inflammation associated with RA.

Here’s what you missed this week on Managed Healthcare Executive.

Illuminate Rx is the country’s first pharmacist-designed pharmacy benefits optimizer (PBO), offering transparent, clinically driven PBM options for brokers and self-funded employers, with a focus on data clarity, flexible formulary design and specialty pharmacy partnerships, according to Robert Gamble, CEO of RxBenefits.

Diagnosed with triple-negative breast cancer at age 36 and now in remission, Deanna Gerber, M.D., gynecologic oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital, says her experience has made her a better physician and advocate for her patients.

A decline in PrEP coverage could reverse HIV prevention gains, causing tens of thousands of preventable infections and billions in added healthcare costs, a new JAMA Network Open study finds.

The new JAMA + Women’s Health multimedia channel focuses on all aspects of women’s health, not just topics like menopause or ovarian cancer, presenting content from across JAMA and JAMA Network in one place.

Use of transparent PBMs has surged as employer reliance on the Big Three declines, highlighting shifting strategies to address escalating healthcare costs, the Pulse of the Purchaser 2025 survey finds.